rsglt2

Canagliflozin (JNJ 28431754AAA) is a selective SGLT2 inhibitor that inhibits CHO cells expressing mSGLT2, rSGLT2, and hSGLT2 (IC50=2/3.7/4.4 nM). Canagliflozin can be used for the treatment of type II diabetes mellitus (T2DM).

Canagliflozin hemihydrate (TA 7284) is a drug of the gliflozin class or subtype 2 sodium-glucose transport inhibitors used for the treatment of type 2 diabetes. SGLT2 is responsible for at least 90% of renal glucose reabsorption (SGLT1 being responsible for the remaining 10%). Blocking this transporter causes up to 119 grams of blood glucose per day to be eliminated through the urine, corresponding to 476 kilocalories.

Remogliflozin etabonate (GSK189075A) is a prodrug of regaliflozin and an inhibitor SGLT2 with Ki values of 1.95, 2.14, 8.57, and 43.1μM for hSGLT2, rSGLT2, rSGLT1, and hSGLT1, respectively.

Remogliflozin etabonate-d7 (GSK189075-d7) is a deuterium-labeled form of Remogliflozin etabonate. Remogliflozin etabonate (GSK189075), an orally active, selective, and low-affinity sodium-glucose co-transporter (SGLT2) inhibitor, exhibits Ki values of 1.95 μM for hSGLT2, 43.1 μM for rSGLT2, 2.14 μM for hSGLT1, and 8.57 μM for rSGLT1. As a benzylpyrazole glucoside-based prodrug, it is metabolized in vivo to its active form, Remogliflozin, and demonstrates antidiabetic efficacy in rodent models.

Canagliflozin (Standard) is the standard substance of Canagliflozin, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Canagliflozin (JNJ 28431754AAA) is a selective SGLT2 inhibitor that inhibits CHO cells expressing mSGLT2, rSGLT2, and hSGLT2 (IC50=2/3.7/4.4 nM). Canagliflozin can be used for the treatment of type II diabetes mellitus (T2DM).